Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2015

View Archived Issues

FDA grants QIDP status to WCK-5222

Vitae Pharmaceuticals begins phase IIa trial of VTP-38543 in atopic dermatitis

First subject dosed in phase I trial of TD-1473

COTI-2 advances into human testing

NORD receives FDA grant to study natural history of rare diseases

Preclinical efficacy of first-in-class TCB antibody EM-801

DMC recommends continuation of phase III trial of AGS-003 in RCC following second interim analysis

Janssen starts first-in-human trial of Aduro's ADU-214 in patients with NSCLC

Anti-HLA-DR antibody IMMU-114 demonstrates activity in first-in-human study

Burixafor/G-CSF promote impressive hematopoietic stem cell mobilization in MM, NHL and HL patients

Interim phase II data for isatuximab in refractory/relapsed multiple myeloma

Ularitide receives FDA fast track designation for acute decompensated heart failure

Agreements signed by Bristol-Myers Squibb, Kyorin, Novartis, Rhizen, AGTC and Synpromics

Ninlaro now available in the U.S.

Synergy seen with CDK9 inhibitors and venetoclax in lymphoma cells

ACE-083 increases muscle volume in phase I study

FDA approves Vistogard to treat overdose or severe toxicities due to 5-FU or capecitabine

GlaxoSmithKline patents ROR-gamma modulators

Mitsubishi Tanabe Pharma discloses MC1 receptor agonists

Novartis reports MALT1 inhibitors

Medshine Discovery introduces anti-HBV compounds

Pfizer discloses Nav1.7 channel blockers

Merck & Co. patents GPR40 agonists

Preclinical and clinical data reported for multiple myeloma candidate ACY-241

Chimeric antigen receptor-modified T cells induce partial remission in first AML patient treated

FDA grants accelerated approval to Alecensa

FDA approves Otiprio for pediatric patients undergoing tympanostomy tube placement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...